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Abstract: Personalised medicine is the future and hope for many patients, including those with 
cancers. Early detection, as well as rapid, well-selected treatment, are key factors leading to a good 
prognosis. MicroRNA mediated gene regulation is a promising area of development for new diag-
nostic and therapeutic methods, crucial for better prospects for patients. Bladder cancer is a frequent 
neoplasm, with high lethality and lacking modern, advanced therapeutic modalities, such as im-
munotherapy. MicroRNAs are involved in bladder cancer pathogenesis, proliferation, control and 
response to treatment, which we summarise in this perspective in response to lack of recent review 
publications in this field. We further performed a correlation-based analysis of microRNA and gene 
expression data in bladder cancer (BLCA) TCGA dataset. We identified 27 microRNAs hits with 
opposite expression profiles to genes involved in immune response in bladder cancer, and 24 mi-
croRNAs hits with similar expression profiles. We discuss previous studies linking the functions of 
these microRNAs to bladder cancer and assess if they are good candidates for personalised medi-
cine therapeutics and diagnostics. The discussed functions include regulation of gene expression, 
interplay with transcription factors, response to treatment, apoptosis, cell proliferation and angio-
genesis, initiation and development of cancer, genome instability and tumour-associated inflamma-
tory reaction. 




Traditionally, cancer patients have been prescribed their medications based on the 
tissue of origin, but also symptoms and signs of their disease, according to the rule “one 
size fits all” [1]. Personalised medicine is a leading medical model proposing customisa-
tion of healthcare [1,2]. According to this strategy, treatment and all medical procedures 
should be tailored to the particular patient, especially to their genetic makeup, not only 
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the disease. Thus, stratified medicine is a concept based on identifying subgroups of pa-
tients having distinct characteristics, mechanisms of disease or responses to treatment [3].  
Not only the treatment is tailored in this concept, it also requires very precise diag-
nostic tests, able to identify a subgroup of patients which will benefit from the treatment 
or those patients whose health might be at risk when given certain drugs. Particularly 
prominent diagnostic procedures include genomics-based molecular methods, with the 
aid of imaging and analytical/bioinformatical tools. Development of molecular personal-
ised medicine requires interdisciplinary teams composed of medical and biological speci-
alities. It requires a good understanding of human organism complexity, environmental 
exposures, genomic interactions and the disease process itself [1]. 
Unfortunately, precision medicine is being implemented very slowly in cancer man-
agement. The need for good biomarkers is more urgent than ever. For example, platinum-
based chemotherapy and/or cystectomy remain the major clinical interventions under-
taken for bladder cancer patients. However, the only factors considered for the selection 
of therapy are the disease progression and responsiveness to chemotherapy [4,5]. Given 
the incredible progress in immunotherapy, the need for clinically useful biomarkers and 
molecular methods for patient stratification is obvious, as only approximately 50% of the 
patients respond to chemotherapy. Another group responds well to checkpoint inhibitors 
(in most cases 15–30%; depending on the drug and trial, it can be up to 46%) to give some 
examples [4].  
MicroRNAs (miRNAs, miRs) are abundant small non-coding RNAs composed of 22–
24 nucleotides [6,7]. They play an important role in post-transcriptional gene suppression 
[8] and have been reported to be involved in cellular processes, such as differentiation, 
morphogenesis and tumorigenesis [8,9]. miRNAs usually target the 3’unranslated region 
(UTR) of the mRNA and less frequently the 5’UTR or the coding sequence of their target 
mRNA [9]. Thus, miRNAs regulate gene expression, and each miRNA molecule targets 
tens to hundreds of mRNAs [6]. Furthermore, some mRNA targets might be combinator-
ically affected by several different miRNA molecules, increasing the complexity and pre-
cision of post-transcriptional regulation, and fine-tuning the expression level of genes [6]. 
Aberrant miRNA expression is found in a variety of cancers, including bladder cancer, 
suggesting that they may have roles as oncogenes or tumour-suppressor genes [8]. Half 
of all the miRNA genes are located in genomic regions known to be associated with cancer 
or in fragile sites often altered in human cancers [9]. These observations clearly show the 
importance of miRNAs function in cancer. 
Selected groups of specific miRNAs are commonly altered in particular cancers, and 
recent data have shown that miRNA expression profiles of tumours are able to discriminate 
between different types of cancer [10]. Thus, miRNA profiles might be more useful for can-
cer diagnosis and prognosis [11], whereas profiles based only on mRNA have been proven 
to be generally unreliable, to date [10]. Several miRNA:mRNA interactions have been 
proven to be important for cancer pathogenesis so far, with let-7 miRNA family being the 
most well-studied [12]. The family of miR let-7 regulates RAS oncogenes, among others, and 
the expression of let-7 is reduced in several tumours, including lung cancer [12]. 
At the moment, there are no reliable molecular biomarkers for bladder cancer prog-
nosis, treatment, response or progression, despite advances achieved through novel 
checkpoint therapies [13,14]. Significant effort has been invested in unravelling predictive 
biomarkers for the response to immune checkpoint inhibition in many cancers, including 
bladder cancer, melanoma or lung cancer [13,15]. PD-1/PD-L1 expression in tumour cells 
and in the tumour microenvironment, genetic alterations, mutational load in tumour cells, 
epigenetic changes, miRNAs expression, pre-existing immunity and its enhancement dur-
ing treatment by the tumour-infiltrating immune cells were associated with better out-
comes and were shown to be predictors for immune checkpoint inhibition. However, fur-
ther studies are required to assess their predictive power and facilitate the implementation 
into the clinic [13,15]. In this paper, we present results from a comprehensive bioinformat-
ical analysis of the correlation between the expression of 21 genes known to be involved 
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in the immunological synapse and miRNAs in bladder cancer. We also added three tran-
scription factors discovered in our previous work [16] to be positively correlated with the 
expression of selected checkpoint mRNAs from the network we previously reported.  
2. Results 
2.1. Correlations Analyses in Bladder Cancer Samples—Genes mRNA to miRNA 
In this study, we investigated co-expression profiles of miRNAs and co-inhibitory 
and co-stimulatory checkpoint genes potentially involved in the immunological synapse. 
To facilitate this task, we visualised the correlations as both static and interactive 
heatmaps for the bladder cancer dataset available in The Cancer Genome Atlas (TCGA). 
This resource is now available publicly as an interactive website (see Supplementary Ma-
terials section, Figures S1 and S2). 
In order to create a good starting point for further investigations aiming to assess 
regulatory dependencies and genetic interactions between genes and microRNAs, we cal-
culated correlations between all miRNAs and a selected set of 21 genes, known from the 
literature to be potentially expressed on the cancer side of the immunological synapse: 
CD112, CD137L, CD200, CD276, CD277, CD40, CD48, CD70, CD80, CD86, GITRL, 
HHLA2, HVEM, ICOSLG, LGALS9, OX40L, PD−L1, PD−L2, PVR, VISTA and VTCN1. To 
present a more complete picture of regulation, we also included three transcription factors 
(TFs), which we identified in our previous research to be correlated with the co-expressed 
checkpoint genes in this set: BACH2, MAFK and NFE2L2 [16]. 
We chose to further study miRNAs that are negatively correlated with gene expres-
sion under our assumptions that these may directly negatively regulate one of the genes 
of interest. Conversely, positive correlation might indicate indirect regulation; for exam-
ple, miRNAs that negatively regulate suppressors of the genes of interest, but may also 
indicate more complex crosstalk. Using these criteria, we obtained 27 miRNAs generally 
anti-correlated with gene expression: hsa−mir−30d, mir−4778, mir−1306, mir−4756, 
mir−1287, mir−96, mir−3200, mir−187, mir−93, mir−423, mir−219a−1, mir−98, mir−182, 
mir−1307, mir−744, mir−301b, mir−940, mir−151a, mir−3193, mir−183, mir−191, mir−141, 
mir−7706, mir−200c, mir−429, mir−200b and mir−200a (Figure 1).  
The correlation profiles of all 27 miRNAs are very similar, suggesting that they all 
contribute to the co-suppression of immune synapse genes. However, their correlation 
with genes is not uniform: CD48 CD70, CD80, CD86, OX40L and PD−L2 are most strongly 
anticorrelated to miRNA expression, indicating that this cluster of genes is under the 
strongest control. In the previous report [16], we found most of these genes to be strongly 
correlated with each other and possibly working together in synergy. At the same time, 
the results suggest the existence of a second set of genes that are not anticorrelated or 
weakly correlated with the set of putative downregulating miRNAs: CD112, VEM, 
ICOSLG, LGALS9 and VTCN1. Interestingly, we found these genes correlated with other 
genes in the immune response set—this intuitively suggests that not all, but only a specific 
subset of immune response genes is under specific miRNA control. 
The TCGA database contains the expression levels of pre-miRNAs and not of the 
mature miRNAs. Some of the top correlated and anticorrelated miRNAs, for example, 
mir-199a-1 and mir-199a-2, have different pre-miRNA sequence, but produce identical 
mature miRNA, and are extremely likely to target the same genes. Furthermore, among 
our top hits, there are miRNAs, which have a different mature sequence, but share the 
same seed region such as mir-146a and mir-146b, and are also likely to target the same 
genes. However, their transcriptional and post-transcriptional regulation might be differ-
ent, and they can potentially perform different functions depending on transcription of 
other miRNAs and coding genes. We observed identical correlation profiles for some miR-
NAs sharing the mature sequence (mir-125b-1 and mir-125b-2). However, the expression 
profiles were similar, but not identical for miRNAs, sharing only the seed region: mir-
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146a and mir-146b; mir-199a and mir-199b. Additionally, mir-199a−1 and mir-199a−2, de-
spite sharing an identical sequence, had similar, but not identical correlation profiles. 
We also obtained 19 miRNAs generally correlated with gene expression: mir−155, 
mir−146b, mir−142, mir−146a, mir−29a, mir−150, mir−4772, mir−5586, mir−223, mir−7702, 
mir−199b, mir−100, mir−199a−2, mir−511, mir−125b−1, mir−125b−2, mir−199a−1, mir−221 
and mir−21 (Figure 2). In this case, it is more difficult to speculate if this positive correla-
tion indicates indirect regulation or these miRNAs are generally upregulated in cancer 
alongside immune response genes and are responsible for different functions, for example 
suppressing an unrelated set of genes. 
 
Figure 1. Heatmap showing negative correlations between selected genes active at cancer side of the immunological syn-
apse: CD112, CD137L, CD200, CD276, CD277, CD40, CD48, CD70, CD80, CD86, GITRL, HHLA2, HVEM, ICOSLG, 
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miRNA. Negative correlations are shown in blue. The numbers in heatmap tiles represent the correlation coefficients. The 
following statistical criteria were used to filter miRNA: correlation coefficient <= −0.2 for anticorrelated microRNAs and 
statistical significance of correlation (p-value from cor.test function in R) < 0.01. 
 
Figure 2. Heatmap showing positive correlations between selected genes active at cancer side of the immunological syn-
apse: CD112, CD137L, CD200, CD276, CD277, CD40, CD48, CD70, CD80, CD86, GITRL, HHLA2, HVEM, ICOSLG, 
LGALS9, OX40L, PD−L1, PD−L2, PVR, VISTA and VTCN1, transcription factors: BACH2, MAFK and NFE2L2 and 
miRNA. Positive correlations are shown in red. The numbers in heatmap tiles represent the correlation coefficient. The 
following statistical criteria were used to filter miRNA: correlation coefficient >= 0.2 for correlated microRNAs and statis-
tical significance of correlation (p-value from cor.test function in R) < 0.01. 
2.2. Correlations Analyses in Bladder Cancer Samples—Genes to Genes 
To better understand the impact of underlying gene regulatory network on genes-
miRNA interactions, we analysed the correlations between the genes and transcription 
factors only. These created a symmetric correlation heatmap (Figure 3), which we further 
projected as a correlation-driven network using a force-directed layout (Figure 4). 
The genes that we previously observed to be well-correlated and anticorrelated to 
miRNA hits, CD48 CD70 CD80 CD86 OX40L PD−L1 PD−L2, show a good correlation with 
each other resulting in a distinctive cluster (Figure 4). Additionally, the BACH2 transcrip-
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strongly correlated, or strongly correlated only to a single gene within the cluster, rather 
than forming further cliques.  
 
Figure 3. Heatmap showing correlations between selected genes active at cancer side of the immunological synapse: 
CD112, CD137L, CD200, CD276, CD277, CD40, CD48, CD70, CD80, CD86, GITRL, HHLA2, HVEM, ICOSLG, LGALS9, 
OX40L, PD−L1, PD−L2, PVR, VISTA and VTCN1, transcription factors: BACH2, MAFK and NFE2L2. Positive correlations 
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Figure 4. Expression correlation network showing genes active at cancer side of the immunological synapse (red nodes): 
CD112, CD137L, CD200, CD276, CD277, CD40, CD48, CD70, CD80, CD86, GITRL, HHLA2, HVEM, ICOSLG, LGALS9, 
OX40L, PD−L1, PD−L2, PVR, VISTA and VTCN1 and transcription factors (blue nodes): BACH2, MAFK and NFE2L2. 
Green lines represent positive correlations, and red lines represent negative ones. Line thickness represents the strength 
of the correlation. 
2.3. Correlations Analyses in Bladder Cancer Samples—miRNA to miRNA 
To investigate if gene–miRNA interaction is influenced by a specific pattern of corre-
lations between miRNAs themselves, we analysed the correlations within previously 
identified miRNA hits. Figure 5 and Figure 6 show correlations within negatively and 
positively correlated miRNA hits, respectively. We also projected these correlations on the 
































Figure 5. Heatmap showing correlations within miRNA hits negatively correlated to checkpoint genes. Positive correla-
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Figure 6. Heatmap showing correlations within miRNA hits positively correlated to checkpoint genes. Positive correla-
tions are shown in red, negative correlations are shown in blue. The numbers in heatmap tiles represent the correlation 
coefficients. 
As expected, both groups of miRNAs were well-correlated within each set, with the 
correlation of 1 or close to one for miRNAs leading to the same mature microRNA. How-
ever, we observed some examples of nearly identical expression profiles between different 
miRNAs, for example, hsa−mir−429, hsa−mir−200b and hsa−mir−200a in negative hits; and 
hsa−mir−199b, hsa−mir−100, hsa−mir−199a−2, hsa−mir−125b−1 and hsa−mir−125b−2 
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When visualised as a network, correlations within miRNA targets showed similar 
expression profiles within positive and negative hit groups. Between these two groups, 
correlations were negative indicating—as expected—opposite expression patterns. Inter-
estingly, we observed a further sub-clustering within both groups. Positive hits formed 
two distinct clusters, while negative hits formed two smaller, tightly correlated cliques 
with other miRNAs more loosely correlated. 
 
Figure 7. Expression correlation network showing positive (blue negative) and negative (red negative) miRNA hits. Green 
lines represent positive correlations and red lines represent negative ones. Line thickness represents the strength of the 
correlation. 
2.4. Network of Correlation Derived Interactions Between miRNAs, Checkpoint Genes and TFs 
We analysed all the dependencies and possible interactions between miRNAs, check-
point genes and TFs. We visualised them and a combined correlation network. Figure 8 
shows the features we discovered in previous steps in a broader context. The gene cluster 
of CD48, CD70, CD80, CD86, OX40L, PD−L1, PD−L2 and BACH2 transcription factor is 
well-connected and visible in between positive and negative miRNA hits territories. Neg-
ative hits show well-connected cliques, that are also better anti-correlated with the cluster 
of checkpoint genes. Positive miRNA hits show two bigger, distinct clusters, of which one 









































































































Figure 8. Combined expression correlation network showing negative (green nodes) and positive (blue nodes) miRNAs 
hits; immunological checkpoint genes (red nodes): CD112, CD137L, CD200, CD276, CD277, CD40, CD48, CD70, CD80, 
CD86, GITRL, HHLA2, HVEM, ICOSLG, LGALS9, OX40L, PD−L1, PD−L2, PVR, VISTA and VTCN1; and transcription 
factors (purple nodes): BACH2, MAFK and NFE2L2. Green lines represent positive correlations and red lines represent 
negative ones. Line thickness represents the strength of the correlation. 
2.5. Immune Synapse Genes are Deregulated in Breast Cancer 
Finally, we analysed how the expression of the immune synapse gene set changes 
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limited since cancer tissue data set in TCGA are much more numerous than normal tissue 
414 and 19 samples, respectively. We obtained gene expression value estimates as frag-
ments per million reads per kilobase of transcript (FPKM) and visualised their distribu-
tions with imposed box statistics in Figure 9. Direct comparison of FPKM distributions 
show us that all three transcription factors: BACH2, MAFK and NFE2L2 are downregu-
lated in cancer cells. CD48, CD200 and VISTA are also downregulated in cancer samples, 
while CD276, LGALS9 and PVR are upregulated in cancer tissue. To understand these 
changes in the context of global expression, we have run differential expression analyses 
using the DEseq2 package. Taking into account a global dispersion and values of the ex-
pression, DEseq found MAFK, NFE2L2, CD200, CD80, HHLA2, LGALS9, PD−L1 (CD274) 
and PVR to be significantly upregulated, while CD112 (PVRIG), CD276, CD48 and VISTA 
(VSIR) are significantly downregulated. It should be noted that as with the very low ex-
pression values, such as BACH2, they are not assigned as significantly deregulated. How-
ever, analysing the distributions of the expression of BACH2 in cancer vs. normal tissue 
we see a small but significant difference. 
 
Figure 9. Comparison of gene expression values in cancer vs. normal tissue. Visualised values represent fragments per 
million reads per kilobase of transcript (FPKM) obtained from TCGA. Violin plots show the distribution of expression 
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The stars above each group indicate the significance level (p-value) derived from Mann–Whitney (Wilcoxon) U test. p-
value mapping go as follows: ***** represents a p-value below 0.00001, **** represents a p-value below 0.0001, *** represents 
a p-value below 0.001, ** represents a p-value below 0.01 and * represents a p-value below 0.1; “NS.” denotes not significant. 
3. Discussion 
It has been suggested that bladder cancer should not be divided merely based on the 
characteristic of muscle invasion, thus generating two groups: muscle-invasive (MIBC, 
around 20% of bladder cancers at diagnosis) vs muscle-non-invasive (NMIBC, over 60% 
at diagnosis), based on the mutations they possess [12]. Both types have been studied ex-
tensively and it is clear that they differ genetically; for example, NMIBC has significantly 
fewer genomic rearrangements and mutations, whereas MIBC is characterised by fre-
quent chromothripsis events, leading to many different aberrations [12]. Thus, currently, 
it is accepted that two types of bladder cancer mentioned above have several subgroups, 
still under investigation. It is clear if miRNAs can be used as biomarkers for these sub-
groups. Interestingly, most of the miRNAs analysed and described here were not previ-
ously reported to be involved in immunological synapse genes regulation. However, they 
were well connected with oncogenesis or cancer invasion events, as well as cancer’s re-
sponse to the therapeutics. 
3.1. The most Positively Correlated miRNAs 
The top hit in correlated miRNAs, mir−155, is a known oncogenic microRNA that 
targets the ELK3 transcription factor that is imperative in the response to hypoxia [17]. It 
was shown to be upregulated in breast cancer and linked to PARP-1 inhibitors response 
[18]. In bladder cancer, this miR is known to be significantly overexpressed, promoting 
tumour growth by repressing DMTF1, a tumour-supressing gene [19].  
The second-best hit, miR-146b, is a known tumour-suppressor targeting TRAF6 in 
gliomas [20]. In fact, this miRNA has been reported to be a tumour-suppressor molecule, 
or conversely, an oncomiR, in many various cancer types [21]. In bladder cancer, it is usu-
ally upregulated, and this event is correlated with the inhibitory effect on the invasion of 
bladder cancer that resulted from the reduction of the matrix metalloproteinase MMP2 
expression. It has also been proven that miR-146b knock-down attenuated ETS2 expres-
sion in cell lines and in mice, with ETS2 being the significant transcription factor for the 
expression of MMP2 [21]. 
Its family ‘cousin,’ miR-146a, is known to be involved in bladder cancer relapse, af-
fecting the function of bladder cancer stem cells both directly and indirectly [22]. It was 
also shown that miR-146a is important for the maintenance of breast cancer stem cells 
during the epithelial–mesenchymal transition (EMT) by suppressing the expression of the 
Notch signalling inhibitor NUMB [23]. It has already been proposed that miR-146a-5p 
levels measured in the urine samples of patients might be used as a prognostic marker for 
bladder cancer [22,24]. Interestingly, miR-146a—our fourth-best hit—is known to mediate 
the suppression of inflammatory response in adipocytes [25], which suggests that it might 
have a similar effect in cases of cancer disease. The expression of the third-best hit, miR-
142-3p, was reported to be linked with reduced regulatory T-cell function in granulomato-
sis [26]. It also suppresses cell proliferation and cell migration in bladder cancer [27]. These 
and other miRNAs found to be the most correlated with the expression of checkpoint 
genes are described in Table 1.   
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Table 1. The most positively correlated miRNAs and their known functions in human cancers, including bladder cancer, 
if such a function was reported. 
miRNA Function References 
hsa-miR-21 
Impact on survival and prognosis in patients with pancreatic can-
cer; exosomal miR-21 promotes proliferation, but also invasion and 
therapy resistance of colon adenocarcinoma cells via its target 
PDCD4; nothing is known about its role in bladder cancer; a lack of 
miR-21 expression in tumor-associated macrophages (TAMs) pro-
motes antitumoral immune response. 
[28–30] 
hsa-miR-29a 
Downregulated in bladder cancer; shows inhibition of proliferation 
in bladder cancer cell lines via PI3K-AKT pathway; acts as a tumour 
suppressor in many cancer types; increased urine levels correlated 
with shorter event-free survival in most cancer types; high expres-




Suggested role in the invasion and metastasis of hepatocellular car-
cinoma; involved in the PI3K/AKT and mTOR pathways in renal 
carcinoma; interestingly, a variant in the miR-100 gene is a protec-
tive factor of childhood acute lymphoblastic leukaemia. 
[36–38] 
hsa-miR-125b 
Suppresses cell proliferation and metastasis by targeting the HAX-1 
gene in esophageal squamous cell carcinoma; regulates IL-1β-in-
duced inflammatory genes through targeting TRAF6-mediated 
MAPKs and NF-κB signaling in human osteoarthritic chondrocytes; 
acts as an oncogene in glioblastoma cells and inhibits cell apoptosis 
through p53 and p38MAPK-independent pathways; has a role in 
conferring the metastatic phenotype among pancreatic cancer cells; 
unknown function in bladder cancer.  
[NO_PRINTED_FORM][39–42] 
hsa-miR-142 Linked to the reduced regulatory T-cell function in granulomatosis; 
suppresses cell proliferation and cell migration in bladder cancer. 
[25,26] 
hsa-miR-146a 
Mediates the suppression of inflammatory response in adipocytes; 
involved in bladder cancer relapse; important for the maintenance 
of breast cancer stem cells during EMT; suggested that the urine 
levels might be possibly used as a prognostic marker for bladder 
cancer; in bladder cancer, it is usually upregulated, and this event is 
correlated with the inhibitory effect on the invasion of cancer cells 
resulting from the reduction of MMP2 expression. 
[20–25][20,21] 
hsa-miR-150 
Acts as a tumour promoter: promotes cell proliferation, migration 
and invasion of cancer cells through targeting PDCD4 (pro-
grammed cell death 4 protein); modulates cisplatin chemosensitiv-
ity and invasiveness of muscle-invasive bladder cancer cells via tar-
geting PDCD4; is suggested as a urinary biomarker for bladder can-
cer progression; its agonist promotes fibrosis in cultured kidney 
cells, while its antagonists decrease pro-inflammatory cytokines and 
pro-fibrotic proteins and increase anti-fibrotic protein SOCS1. 
[43–47] 
hsa-miR-155 
Tumour-promoting and highly oncogenic microRNA that targets 
ELK3 transcription factor functioning in the hypoxia response; up-
regulated in breast cancer and linked to PARP-1 inhibitors re-
sponse; overexpressed in bladder cancer, promoting tumour growth 
by repressing DMTF1. 
[17–19] 
hsa-miR-199a Functions as a tumour suppressor in oral squamous cell carcinoma, 
targeting the IKKβ/NF-κB signalling pathway; inhibits malignant 
[48–52] [NO_PRINTED_FORM] 
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progression of lung cancer through mediating RGS17; serum levels 
were suggested as a potential diagnostic biomarker for detection of 
colorectal cancer; recently discovered to inhibit angiogenesis by tar-
geting the VEGF/PI3K/AKT signalling pathway in an in vitro model 
of diabetic retinopathy; can attenuate aerobic glycolysis and cell 
proliferation in glioblastoma, but the role in bladder cancer remains 
unrevealed.  
hsa-miR-199b 
Downregulated in breast cancer patients; is often associated with 
malignant clinical characteristics; exerts tumour suppressive func-
tions in hepatocellular carcinoma by targeting JAG1 directly; sup-
pression of miR-199b expressions improves apoptosis and reduces 
the cell viability in cervical cancer. 
[53–56] 
hsa-miR-221 
High expression is a poor predictor for glioma; affects proliferation 
and apoptosis of gastric cancer cells (through targeting SOCS3); 
promotes cisplatin resistance in osteosarcoma cells by targeting 
PPP2R2A; the function in bladder cancer is unknown.  
[57–59] 
hsa-miR-223 
Tumour-suppressive, but also oncogenic miR in various cancers; 
targets WDR62 directly in bladder cancer—the knockdown of 
WDR62 in mice significantly inhibited tumour aggressiveness and 
induced the apoptosis of bladder cancer cells; it may also inhibit mi-
gration and invasion of bladder cancer cells. 
[60–64] 
hsa-miR-511 
circZFR promotes cell proliferation and migration by regulating the 
miR-511/AKT1 pathway in hepatocellular carcinoma; promotes pro-
liferation of human hepatoma cells; functions as a tumour suppres-
sor and a prognostic marker in colorectal cancer; contributes to in-
testinal inflammation; significantly altered expression and its target 
AKT3 have negative prognostic value in prostate cancer, but its 
function in bladder cancer remains unknown.  
[65–69] 
hsa-miR-4772 
Significance in bladder cancer and immunological surveillance re-
mains unclear, but a high level in serum exosomes derived from 
stage II and stage III colon cancer patients was negatively associated 
with the risk of recurrence and the risk of death. 
[70,71] 
hsa-miR-5586 
Downregulated in pancreatic and bladder cancers; high levels 
linked to good outcomes in diffuse large B-cell lymphoma (DLBCL); 




Potentially important in colorectal cancer (CRC) progression, but 
significance in bladder cancer remains unclear. [74,75] 
Correlation with the expression of several other miRNAs have been noted, but with 
surprisingly low statistical significance, given the information from the existing papers, 
for example, high miR-34a expression sensitised MIBC to cisplatin, also inhibiting tumor-
igenicity and cancer cells proliferation [76]. Connection with epigenetic changes was also 
observed and reported in the literature: cisplatin-based therapy induces demethylation of 
miR-34a promoter region, and thus, increases its expression [76]. Despite the significance 
of miR-34a in bladder cancer and suggested role in checkpoint immune mechanisms, it 
seems unrelated to the expression of checkpoint genes per se.  
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3.2. The most Anti-Correlated miRNAs 
Our top hit in anticorrelated miRs, mir−200a, is known to often play a role in cancer. 
However, it is reported to regulate the EMT rather than immune response. It is also pre-
dictive for prognosis in colorectal cancer patients. Specifically, in bladder cancer, it was 
reported to be correlated with early-stage and T1 bladder tumour progression [77] and 
bladder cancer invasion [78]. Overexpressed miR-200a is known to promote bladder can-
cer invasion through the direct regulation of the axis Dicer/miR-16/JNK2/MMP-2E [78]. 
Moreover, miR-200a is very important in ovarian carcinoma: it promotes cell invasion and 
migration by targeting PTEN. The only reports of mir-200a involvement in the immune 
response to date come from small airway epithelial cells lung cancer [79]. 
Although the role of hsa-miR-200b has not been clear in bladder cancer, it seems par-
ticularly significant in renal cancer: it is often downregulated and may suppress metastasis 
by targeting LAMA4 in renal cell carcinoma [80]. The significantly aberrant expression has 
also been reported in HER-2 negative breast cancer [81], as well as cardiological pathologies 
and angiogenesis aberrations [82,83]. In breast cancer, it has also been reported that miR-
200b may affect breast cancer cells’ response to tamoxifen, involving MYB [84]. Moreover, 
it has been suggested as a prognostic marker in clear cell renal carcinoma [85]. Finally, epi-
genetic silencing of miR-200b was connected with cisplatin resistance in bladder cancer [86]. 
miR-200c seems to be particularly important in breast cancer pathogenesis and re-
sponse to treatment; for example, several authors indicated its role in cancer cell sensitiv-
ity to therapy, including trastuzumab use in HER2 positive breast cancer [87,88]. Interest-
ingly, miR-200c might act protectively against colorectal cancer through the BMI1 gene 
complex [89]. Furthermore, it suppresses tumour metastasis by inhibiting EMT in oral 
squamous carcinoma [90]. Although its role in bladder cancer remains unknown, the level 
of miR-200c in bladder cancer patients’ urine is significantly different from the level in 
healthy people; thus, it has been suggested as a potential biomarker [32,91].  
In our research, miR-200 family seems to be important in the regulation of several 
checkpoint genes, especially CD48, CD70, CD80, CD86 and PD-L2, as well as transcription 
factor BACH2, which is known to be involved in transcription regulation of these genes. 
This finding suggests that it might be a strong candidate for future investigations, espe-
cially those aiming at biomarker discovery and new drug targets.  
These and other significant miRs revealed in this study are described in Table 2.  
Table 2. The most negatively correlated miRNAs and their known functions in human cancers, including bladder can-
cer, if such a function is reported. 
miRNA Function References 
hsa-miR-30d 
Involved in suppressing endoplasmic reticulum and chaperone and 
signalling regulators in several human cancers; suggested as a tu-
mour supressor in lung cancer initiation and progression. 
[92–96] 
hsa-miR-93 
Probably associated with the prognosis of bladder cancer; known to 
promote bladder cancer cells proliferation and invasion via target-
ing PEDF gene; involved in sensitivity of bladder cancer to chemo-
therapy; promotes hepatocellular carcinoma progression, possibly 
via miRNA-93-5p/MAPK/c-Jun positive feddback loop. 
[97–102] 
hsa-miR-96 
Oncogenic miR; potential urinary biomarker in bladder cancer; in-
volved in EMT and migration and invasion of bladder cancer cells 
via targeting CDKN1A; impacts the response to chemotherapy. 
[103–108] 
hsa-miR-98 
Important in the development and progression of bladder cancer 
due to its involvement in the WNT/β-catenin pathway; promotes 
drug resistance via targeting the LASS2 gene; axis miR-98/IGF1 con-
tributes to breast cancer progression. 
[109–113] 




Might be important in the wound-healing process; promotes blad-
der cancer progression, and thus, has prognostic value; in oesopha-
geal cancer, promotes cell proliferation, migration and invasion; 
moreover, in ameloblastoma, it has been shown to supress cell mi-
gration via upregulation of the NCAM1 molecule. 
[114–117] 
hsa-miR-151a 
Studied in atopic dermatitis, pain transmission and NOTCH2 sig-
nalling pathway; targeting CHL1 inhibits proliferation and invasion 
of colon cancer cells; in nasopharyngeal carcinoma, the inhibition of 




Potentially important in the bladder cancer development, prolifera-
tion and migration; inhibits inflammation, proliferation and migra-




Involved in the cell adhesion modulation and progression of laryn-
geal cancer; reports in bladder cancer indicated its crucial role in 
maintaining the canonical WNT signalling pathway, regulating 
growth and apoptosis; it has also been reported that cisplatin and 
paclitaxel significantly alter the expression of miR-183; potentially 




Oncogene miR known to be involved in proliferation, migration, in-




Linked to the antiviral response and intracellular mechanisms of vi-
ral replication, e.g., may inhibit the replication of human immuno-
deficiency virus in human cells; circulating miR-191 has been pro-
posed as a biomarker of breast cancer, as well as squamous cell car-
cinoma; it has been suggested to regulate endometrial cancer cell 
growth via TET1-mediated epigenetic modulation of APC gene. 
[132–135] 
hsa-miR-200a 
Regulation of EMT; probably predictive for a patient’s prognosis in 
colorectal cancer; reported to be correlated with early-stage and T1 
bladder tumour progression and bladder cancer invasion; when 
overexpressed, it promotes bladder cancer invasion. 
[77,78] 
hsa-miR-200b 
Significant in renal cancer: it is often downregulated and may sup-
press metastasis by targeting LAMA4 in renal cell carcinoma; aber-
rant expression has been reported in HER-2 negative breast cancer 
as well as cardiological pathologies and angiogenesis aberrations; 
may affect breast cancer cells’ response to tamoxifen, involving 
MYB; it has been suggested as a prognostic marker in clear cell re-
nal carcinoma; epigenetic silencing of miR-200b is connected with 
cisplatin resistance in bladder cancer.  
[83–85,136–138] 
hsa-miR-200c 
Important in breast cancer pathogenesis and response to treatment, 
including trastuzumab use in HER2 positive breast cancer; might 
act protectively against colorectal cancer through BMI1 gene com-
plex; it suppresses tumour metastasis by inhibiting EMT in oral 
squamous carcinoma; the role in bladder cancer remains un-
known—the level of miR-200c in bladder cancer patients’ urine is 
significantly different from the level in healthy people, and thus, it 
has been suggested as a potential biomarker. 
[32,87–91] 
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hsa-miR-219a Inhibits colon cancer progression; enhances the radiosensitivity of 
lung cancer cells. 
[139,140] 
hsa-miR-301b 
Accelerates the growth of gastric cancer; promotes the mobility, 
proliferation and EMT in bladder cancer by targeting EGR1; plasma 
levels of miR-301b might be a potential biomarker of early stage 
non-small-cell lung cancer. 
[141–144] 
hsa-miR-423 
It has been proposed as a biomarker, indicating early stages of blad-
der cancer, especially from blood serum and urine; suppression of 




Known to be involved in the pathogenesis of many cancer types, in-
cluding bladder; significant role in EMT in bladder cancer; expres-
sion levels have been correlated with patient outcomes; it seems to 
promote proliferation of bladder cancer cells via the inhibition of 
CDKN2B; elevated miR-429 supresses the progression of hyphopha-
ryngeal squamous cells carcinoma by reducing ZEB1 expression. 
[148–152] 
hsa-miR-744 
Although its function in bladder cancer has to be revealed, it seems 
important in colorectal cancer, ovarian cancer and heart diseases, 
targeting the ARF1 gene; interestingly, it has been reported to be in-
volved in regulation of the MHC class I gene expression; contrib-
utes to inflammation among patients with Sjorgen Syndrome; pro-
motes proliferation of osteosarcoma cells by targeting PTEN.  
[153–157] 
hsa-miR-940 
Known to impact the aggressiveness of bladder cancer cells via acti-
vating the WNT/β-catenin pathway; suggested as a biomarker of 




Probably regulates the MEK/ERK pathway; the role in immune sur-
veillance remains unknown. [162,163] 
hsa-miR-1306 
Connected with the SIRT gene family expression; important in gas-
tric cancer; its role in immune surveillance is to be revealed. [164–166] 
hsa-miR-1307 
Upregulation contributes to the progression of gastric cancer; indi-
cates the metastatic potential of hepatocellular carcinoma; by target-
ing TRAF3 gene, it also regulates the MAPK/NFkB pathway in lung 
adenocarcinoma, promoting cancer cells’ proliferation. 
[167–169] 
hsa-miR-3193 Very little is known about this miR; however, its role has been re-
ported in melanoma pathogenesis. 
[170] 
hsa-miR-3200 Acting in gastric cancer tumorigenesis and progression. [171–173] 
hsa-miR-4756 
Seems to be particularly important in triple-negative breast cancer 
pathogenesis; also reported in the EMT process. [174,175] 
hsa-miR-4778 
Might be involved in radioresistance development in cervical can-
cer. [176] 
hsa-miR-7706 
Little is known about this miR and its function in cancer pathogene-
sis; in hepatocellular carcinoma, it seems to have a prognostic value. [177] 
3.3. Other miRNAs Important in Bladder Cancer 
There are several miRNAs described extensively in the bladder cancer literature, but 
surprisingly, they are not significantly correlated with any of the analysed genes. For ex-
ample, miR-497 was significantly downregulated in bladder transitional cell carcinoma 
cells and tissues [8]. This led to the upregulation of the transcription factor E2F3 and sup-
pression of cell proliferation and invasion [8]. On the other hand, the transcription factor 
E2F has been shown to regulate the expression of miR-15b, a member of the same miR 
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family as miR-497 [137]. Similarly, miR-106a had an inhibitory effect on the proliferation 
of BC cells through the modulation of MAPK signalling [8]. 
Several authors have already emphasised the importance of immune cells infiltra-
tions in the tumour as a key component of the patient’s response to PD-1/PD-L1 check-
point inhibition. Additionally, the presence of specific cells and/or components in the can-
cer microenvironment can be crucial, for example, in myeloid cells. This phenomenon was 
observed not only in melanoma or bladder cancer, but also in other not-so-well-investi-
gated cancer types in terms of immunotherapy, such as pancreatic cancer [178]. Mi-
croRNAs have been shown to be important in the patient’s response to therapy. For in-
stance, in chemoresistant ovarian cancer, miR-424 has been proved to regulate the PD-
1/PD-L1 and CTLA-4/CD80 pathways [179]. The expression of miR-424 is inversely corre-
lated with the expression of PD-1, PD-L1, CTLA-4 and CD80 genes, and it has been shown 
that miR-424 inhibited the expression of those genes through direct binding to the 3’UTRs 
[99]. Moreover, the progression-free survival (PFS) of ovarian cancer patients has been 
positively correlated with high levels of this miR [179]. 
3.4. Limitations to the Research Presented 
As in any research, there are several limitations to our work which need to be men-
tioned. First, our results are based on the retrospective analysis of a single dataset of 402 
cancer samples. The correlations should, therefore, be verified using other data cohorts. 
Secondly, our analysis is based on the expression data. The RNA-seq data do not measure 
the final concentration of protein in the cytoplasm and at the cell surface. With a compre-
hensive proteomics dataset, a more in-depth analysis of actual protein levels and protein–
protein interactions at the cancer cell membrane could be performed. This is especially 
important for the surface proteins of the immunological synapse. 
4. Materials and Methods 
4.1. Data Acquisition and Pre-Processing  
We acquired miRNA expression, mRNA expression and clinical metadata for cancer 
cohorts from The Cancer Genome Atlas (TCGA) database using the “TCGAbiolinks” 
package in R (see Supplementary Materials section). For correlation analyses, we used the 
results of “HTSeq - FPKM” workflows for mRNA and read counts for miRNA. We dis-
carded duplicates of the same patient and selected only for experiments where the match-
ing sample was profiled for gene expression and miRNA expression. Of note, healthy tis-
sue samples marked as “controls” were derived from the same patients from which the 
tumour samples were derived. 
4.2. Correlation Analyses 
Based on the literature, 21 genes potentially expressed at cancer/APC side of the im-
munological synapse were selected for further analyses. We selected mRNAs of interest 
and created an n × m numeric matrix of expression measures representing reads per mil-
lion per kilobase of transcript (RPKM) for RNA-seq, where n is the number of individual 
samples and m is the number of pre-selected mRNAs. In a similar manner, we created a 
matrix presenting microRNA expression values—an n × k numeric matrix of expression 
values, where n is the number of individual samples and k is the number of miRNAs.  
We then generated a nonparametric correlation matrix between miRNA and mRNA 
expression values using Spearman's rank-order correlation coefficient implemented in R. 
The statistical significance of each correlation is determined using a correlation test: a t-
test is applied to the individual correlations using the following formula: t = r* sqrt(n-
2)/sqrt(1-r^2). This method is implemented in the “psych” package. The p-values are then 
corrected to q-values using the false detection rate (FDR) method [179]. The resulting cor-
relations and associated q-values are visualised for further inspection using a custom cor-
relation heatmap drown in “GGplot2” package. Because of the large number of miRNAs, 
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we also provide interactive heatmaps drown using “d3heatmap” package. All interactive 
and full static heatmaps are available in the Supplementary Materials section. For figures 
shown in the manuscript, in the interest of clear visualisation, we have filtered out miR-
NAs with only non-significant or low correlations to 21 re-selected mRNAs. 
4.3. Graphical Model Estimation for Correlation Networks 
Correlation graphs represent the correlation matrix with nodes that indicate genes of in-
terest and edges that represent correlation values. Green edges indicate positive correlations 
and red edges negative ones. The width of the edges and their colour saturation corresponds 
to the absolute value of correlations and scale relative to the strongest weight in the graph. The 
graphs are organised as “spring” layout, which uses the Fruchterman–Reingold algorithm 
[11] to obtain a force-directed layout. In this solution, each node (connected and unconnected) 
repulses the other, while connected nodes attract each other. After a number of iterations (500), 
a final logout is reached—the distance between the nodes corresponds well to the correlation 
between the nodes, where correlated nodes are close to each other, while anticorrelated (neg-
ative correlation) nodes are moved to distant parts of the graph. 
5. Conclusions 
Our results clearly indicate several miRNAs that might be important in post-tran-
scriptional checkpoint genes regulation on tumour side of the immunological synapse. 
Moreover, some microRNAs might indirectly participate in transcriptional regulation of 
checkpoint genes in bladder cancer. Further experimental research is required to confirm 
and quantify these interactions. MicroRNAs acting as moderators of immune response at 
the cancer side of the synapse are promising drug candidates and biomarkers. They can 
be used directly as novel biologics to modulate the synapse, aiming to increase tumour 
immunogenicity, and thus, as the response to the immune checkpoint inhibitor therapy in 
bladder cancer. Despite our better understanding of immune response regulation and 
new checkpoint inhibitor therapeutics being introduced to the market, cisplatin-based 
chemotherapy remains the major therapeutic agent used to treat bladder cancer world-
wide [5]. Only about half of patients respond to this treatment, and eventually, all patients 
develop a chemotherapy resistance [5,180]. Therefore, we see a crucial need for finding 
new, highly individualised therapeutic strategies together with molecular biomarker-
based companion diagnostics. MicroRNAs play a crucial role in many, if not most, of the 
processes leading to the development, growth, invasiveness and progression of the tu-
mour. Given their favourable molecular characteristics and ease of detection, they are 
promising biomarker and therapeutic target candidates. We postulate that further re-
search into the function of microRNA in cancer will yield predictive and prognostic bi-
omarkers to be used in rapid, inexpensive and accurate diagnostics [14]. 
Supplementary Materials: Figure S1: Heatmap showing all corelations between selected gens and 
miRNAs as PDF; Figure S2: Interactive heatmap showing all corelations between selected gens and 
miRNAs—online resource at https://przemol.github.io/blca/ [181,182]. 
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